Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma – the phase III “PREVENT”- (FLOT9) trial of the AIO /CAOGI /ACO

被引：0

作者：

Thorsten O. Götze

Pompiliu Piso

Sylvie Lorenzen

Ulli S. Bankstahl

Claudia Pauligk

Moustafa Elshafei

Giuseppe Amato

Daniel Reim

Wolf O. Bechstein

Alfred Königsrainer

Stefan P. Mönig

Beate Rau

Matthias Schwarzbach

Salah-Eddin Al-Batran

机构：

[1] Institute of Clinical Cancer Research (IKF) at Krankenhaus Nordwest,Department for General and Visceral Surgery

[2] UCT-University Cancer Center,Third Department of Internal Medicine (Hematology/Medical Oncology), Klinikum Rechts der Isar

[3] Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest,Department of General Surgery and Emergency

[4] Hospital Barmherzige Brueder,Klinik und Poliklinik für Chirurgie, Klinikum rechts der Isar

[5] University of Regensburg,Department of General and Visceral Surgery

[6] Technische Universitat Munchen,Department of General

[7] Bariatrische und Metabolische Chirurgie,, Visceral Surgery and Transplantation

[8] Krankenhaus Nordwest,Service de Chirurgie viscérale

[9] University of Palermo,Department of Surgery

[10] Technische Universität München,undefined

[11] University Hospital Frankfurt,undefined

[12] University Hospital Tübingen,undefined

[13] Hôpitaux Universitaires de Genève,undefined

[14] Campus Charité Mitte,undefined

[15] Campus Virchow-Klinikum CCM/CVK,undefined

[16] Clinic for General,undefined

[17] Visceral,undefined

[18] Vascular and Thoracic Surgery,undefined

[19] Klinikum Frankfurt Höchst,undefined

来源：

BMC Cancer | / 21卷

关键词：

Gastric cancer; Gastroesophageal junction cancer; Lauren- classification; Signet ring cells; HIPEC; Hyperthermic intraperitoneal chemotherapy; FLOT- regimen; Gastrectomy; Quality of life; Cisplatin; Peritoneal carcinomatosis;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 40 条

[21] A randomized, open-label, phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKFS633/DANTE trial, a trial of AIO in collaboration with SAKK
Al-Batran, Salah-Eddin
Lorenzen, Sylvie
Thuss-Patience, Peter C.
Homann, Nils
Schenk, Michael
Lindig, Udo
Heuer, Vera
Kretzschmar, Albrecht
Goekkurt, Eray
Haag, Georg Martin
Riera-Knorrenschild, Jorge
Bolling, Claus
Hofheinz, Ralf-Dieter
Angermeier, Stefan
Ettrich, Thomas Jens
Siebenhuener, Alexander Reinhard
Kopp, Christina
Pauligk, Claudia
Goetze, Thorsten Oliver
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[22] A randomized, open-label phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF633/DANTE trial, a trial of AIO in collaboration with SAKK
Al-Batran, Salah-Eddin
Lorenzen, Sylvie
Heuer, Vera
Angermeier, Stefan
Ettrich, Thomas Jens
Homann, Nils
Haag, Georg Martin
Kurreck, Annika
Stein, Alexander
Heinemann, Volker
Ronellenfitsch, Ulrich
Zander, Thomas
Kubicka, Stefan
Siebenhuener, Alexander Rheinhard
Kopp, Christina
Pauligk, Claudia
Goetze, Thorsten
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[23] Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.
Al-Batran, Salah-Eddin
Lorenzen, Sylvie
Thuss-Patience, Peter C.
Homann, Nils
Schenk, Michael
Lindig, Udo
Heuer, Vera
Kretzschmar, Albrecht
Goekkurt, Eray
Haag, Georg Martin
Knorrenschild, Jorge Riera
Bolling, Claus
Hofheinz, Ralf-Dieter
Angermeier, Stefan
Ettrich, Thomas Jens
Siebenhuener, Alexander
Kopp, Christina
Pauligk, Claudia
Goetze, Thorsten Oliver
Gaiser, Timo
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[24] Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK
Al-Batran, S-E.
Lorenzen, S.
Homann, N.
Thuss-Patience, P. C.
Schenk, M.
Lindig, U.
Kretzschmar, A.
Heuer, V.
Goekkurt, E.
Haag, G. M.
Knorrenschild, J. Riera
Bolling, C.
Hofheinz, R. D.
Siebenhuener, A. R.
Irahara, N.
Kopp, C.
Waberer, L.
Pauligk, C.
Gotze, T. O.
Gaiser, T.
ANNALS OF ONCOLOGY, 2021, 32 : S1069 - S1069
[25] FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2-Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group
Hofheinz, Ralf-Dieter
Merx, Kirsten
Haag, Georg M.
Springfeld, Christoph
Ettrich, Thomas
Borchert, Kersten
Kretzschmar, Albrecht
Teschendorf, Christian
Siegler, Gabriele
Ebert, Matthias P.
Goekkurt, Eray
Mahlberg, Rolf
Homann, Nils
Pink, Daniel
Bechstein, Wolf
Reichardt, Peter
Flach, Hagen
Gaiser, Timo
Battmann, Achim
Oduncu, Fuat S.
Loose, Maria
Sookthai, Disorn
Pauligk, Claudia
Goetze, Thorsten O.
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (32) : 3750 - +
[26] HER-FLOT: Trastuzumab in combination with FLOT as perioperative treatment for patients with HER2-positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the AIO Gastric Cancer Study Group.
Hofheinz, Ralf
Hegewisch-Becker, Susanna
Thuss-Patience, Peter C.
Kunzmann, Volker
Fuchs, Martin
Graeven, Ullrich
Homann, Nils
Heinemann, Volker
Pohl, Michael
Tannapfel, Andrea
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[27] Frequency of PD-L1 positivity and microsatellite instability (MSI) in the DANTE trial: Perioperative atezolizumab with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma. A randomized, open-label phase IIb trial of the German gastric group at the AIO and SAKK
Kopp, C.
Lorenzen, S.
Gaiser, T.
Thuss-Patience, P. C.
Schenk, M.
Lindig, U.
Kretzschmar, A.
Heuer, V.
Goekkurt, E.
Haag, G. M.
Knorrenschild, J. Riera
Bolling, C.
Hofheinz, R. D.
Siebenhuener, A. R.
Irahara, N.
Waberer, L.
Pauligk, C.
Gotze, T. O.
Homann, N.
Al-Batran, S-E.
ANNALS OF ONCOLOGY, 2021, 32 : S1069 - S1070
[28] PD-L1 mRNA expression in patients with resectable gastric cancer and adenocarcinoma of the oesophago-gastric junction undergoing perioperative chemotherapy: Results from the FLOT4 phase III trial of the AIO.
Waberer, Lisa
Homann, Nils
Wirtz, Ralph M.
Schmalenberg, Harald
Haag, Georg Martin
Schuler, Martin H.
Kasper, Stefan
Goetze, Thorsten Oliver
Pauligk, Claudia
Hofheinz, Ralf
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[29] Pathological response to neoadjuvant 5-FU, oxaliplatin and docetaxel (FLOT) versus epirubicin, cisplatin and 5-FU (ECF) in patients with locally advanced, resectable gastric/esophagogastric junction (EGJ) cancer: Data from the phase II part of the FLOT4 phase III study of the AIO
Pauligk, C.
Tannapfel, A.
Meiler, J.
Luley, K. B.
Kopp, H. G.
Homann, N.
Hofheinz, R. D.
Schmalenberg, H.
Probst, S.
Haag, G. M.
Egger, M.
Behringer, D. M.
Stoehlmacher, J.
Prasnikar, N.
Block, A.
Trojan, J.
Folprecht, G.
Pohl, M.
Schirmacher, P.
Al-Batran, S. E.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S728 - S728
[30] Interim safety analysis of a phase III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: The AIO-sto-0210 FLOT4 study
Pauligk, Claudia
Meiler, Johannes
Hofheinz, Ralf Dieter
Kopp, Hans-Georg
Mayer, Frank
Schmalenberg, Harald
Luley, Kim
Haag, Georg Martin
Schmiegel, Wolff H.
Homann, Nils
Probst, Stephan
Koenigsmann, Michael
Prasnikar, Nicole
Trojan, Jorg
Egger, Matthias
Mahlberg, Rolf
Heike, Michael
Tannapfel, Andrea
Jaeger, Elke
Al-Batran, Salah-Eddin
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)

← 1 2 3 4 →